Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT03596073Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of calcipotriol in breast cancer (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Changes in the magnitude of CD3+ T cell infiltration in tumor microenvironment at 3 weeks. Started Nov 2018; status: terminated.
02
Drugs
calcipotriol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03596073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596073.